AR119955A1 - METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT - Google Patents
METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPTInfo
- Publication number
- AR119955A1 AR119955A1 ARP200102539A ARP200102539A AR119955A1 AR 119955 A1 AR119955 A1 AR 119955A1 AR P200102539 A ARP200102539 A AR P200102539A AR P200102539 A ARP200102539 A AR P200102539A AR 119955 A1 AR119955 A1 AR 119955A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- methods
- aav2
- ocular neovascular
- treatment
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan métodos para tratar una enfermedad neovascular ocular en un individuo, que comprenden administrar una dosis unitaria de partículas de virus adenoasociado recombinante (rAAV) al ojo del individuo, en el que las partículas de rAAV comprenden: a) un ácido nucleico que codifica un polipéptido que comprende una secuencia de aminoácidos con al menos aproximadamente un 95% de identidad con la secuencia de aminoácidos de SEQ ID Nº 35 y flanqueada por repeticiones terminales invertidas (ITR) de AAV2, y b) una proteína de la cápside de AAV2 que comprende una secuencia de aminoácidos LGETTRP (SEQ ID Nº 14) insertado entre las posiciones 587 y 588 de la proteína de la cápside, en la que la numeración de los residuos de aminoácidos corresponde a VP1 de una proteína de la cápside de AAV2.Methods of treating ocular neovascular disease in an individual are provided, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to the individual's eye, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITR), and b) an AAV2 capsid protein comprising a amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, in which the amino acid residue numbering corresponds to VP1 of an AAV2 capsid protein.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899070P | 2019-09-11 | 2019-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119955A1 true AR119955A1 (en) | 2022-01-26 |
Family
ID=80782130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102539A AR119955A1 (en) | 2019-09-11 | 2020-09-11 | METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR119955A1 (en) |
-
2020
- 2020-09-11 AR ARP200102539A patent/AR119955A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| NZ765038A (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| NZ748395A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| BR112022004027A2 (en) | Methods to treat ocular neovascular diseases using aav2 variants encoding aflibercept | |
| JP2020510428A5 (en) | ||
| MX2021005517A (en) | Gene therapy for neuronal ceroid lipofuscinoses. | |
| CL2020000295A1 (en) | Factor viii (fviii) gene therapy methods | |
| AR124119A2 (en) | MODIFIED VIRAL PARTICLES AND THEIR USES | |
| RU2019103488A (en) | METHODS AND COMPOSITIONS FOR TREATING RDH12-RELATED DISORDERS AND DISEASES | |
| RU2019126509A (en) | Isolated modified protein VP1 of the capsid of adeno-associated virus serotype 5 (AAV5), capsid and vector based on it | |
| AR041964A1 (en) | HCV VACCINE UNDERSTANDING A POLINUCLEOTIDE | |
| CO2022015313A2 (en) | Variants of aav capsids and uses thereof | |
| CL2023001876A1 (en) | Viral capsid proteins with specificity for cardiac tissue cells | |
| UY38881A (en) | METHODS FOR THE TREATMENT OF EYE NEOVASCULAR DISEASES USING AFLIBERCEPT VARIANTS OF AAV2 | |
| JP2020533968A (en) | Recombinant adeno-associated vector | |
| AR119955A1 (en) | METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT | |
| CL2023001650A1 (en) | Danon disease treatment | |
| BR112022003206A2 (en) | METHODS TO TREAT NEOVASCULAR EYE DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPTE | |
| MX2023012410A (en) | Methods of treating ocular diseases using aav2 variants encoding aflibercept. | |
| MX2023002695A (en) | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof. | |
| PE20241336A1 (en) | MODIFIED VP1 CAPSID PROTEIN ISOLATED FROM ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED ON IT | |
| AR128450A1 (en) | VECTORS OF RECOMBINANT ADENO-ASSOCIATED VIRUSES, AND METHODS OF USE THEREOF | |
| PE20241345A1 (en) | VP1 PROTEIN MODIFIED AND ISOLATED FROM THE CAPSID OF ADENOASOCIATED VIRUS SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON THIS | |
| AR122260A1 (en) | USEFUL COMPOSITIONS FOR THE TREATMENT OF POMPE'S DISEASE | |
| EA202192973A1 (en) | COMPOSITIONS USEFUL IN THE TREATMENT OF POMPE DISEASE |